Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Celltrion biopharmaceutical plant, Incheon

Order year

November 2002


Songdo New City, Incheon, South Korea

Estimated investment



2005, validation to be carried out in early 2006 with full production by mid 2006


Phase two of the plant to give an additional 180,000l of capacity is expected to be complete by 2010

Output chemicals

Vaccines, protein therapeutics and monoclonal antibodies


Celltrion (Vaxgen is no longer involved having sold its interest in the company)

Lead engineer / designer

Fluor Enterprises, Daewoo Engineering and Construction, BioEngineering, Foster Wheeler

Other contractors

Emerson Process Management, Amersham, Millipore


Fluor Enterprises, VaxGen QA


Vaxgen (48%), Nexol and Nexol Biotech (13%), Korean Tobacco and Ginseng (13%), J. Stephen and Co Ventures (13%) and others (8%)

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top